Steroid hormone synthetic pathways in prostate cancer

@inproceedings{Mostaghel2013SteroidHS,
  title={Steroid hormone synthetic pathways in prostate cancer},
  author={Elahe A. Mostaghel},
  booktitle={Translational andrology and urology},
  year={2013}
}
While androgen deprivation therapy (ADT) remains the primary treatment for metastatic prostate cancer (PCa) since the seminal recognition of the disease as androgen-dependent by Huggins and Hodges in 1941, therapy is uniformly marked by progression to castration-resistant prostate cancer (CRPC) over a period of about 18 months, with an ensuing median survival of 1 to 2 years. Importantly, castration does not eliminate androgens from the prostate tumor microenvironment. Castration resistant… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Progesterone receptor in the prostate: A potential suppressor for benign prostatic hyperplasia and prostate cancer.

The Journal of steroid biochemistry and molecular biology • 2017
View 4 Excerpts
Highly Influenced

Androgen Signaling in Prostate Cancer.

Cold Spring Harbor perspectives in medicine • 2017

References

Publications referenced by this paper.
Showing 1-10 of 113 references

Evidence for steroidogenic potential in human prostate cell lines and tissues.

The American journal of pathology • 2012
View 14 Excerpts
Highly Influenced

Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2005
View 12 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…